



9 July 2015

ASX RELEASE

Notice of despatch of share purchase plan (SPP) offer materials

Further to the announcement of the SPP on 3 July 2015, Anatara Lifesciences Limited ACN 145 239 872 (ASX: ANR) (**Anatara**), has finalised despatch of the following SPP offer materials:

- 1 an investment overview, which includes details on pricing, the timetable, intended use of funds and key risks of an investment in Anatara;
- 2 SPP terms; and
- 3 an application form.

Information about Anatara is available at www.anataralifesciences.com, which should be considered in conjunction with the company's continuous disclosure to ASX.

For more information please contact:

General inquiries

Mel Bridges
Chairman
+61 (0) 413 051 600
melbridges@parmacorp.com

Media inquiries

Gavin Lower
Buchan Consulting
+61 3 8866 1215
glower@buchanwe.com.au

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

For personal use only

